Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
44 hedge funds and large institutions have $23.6M invested in Talis Biomedical Corporation Common Stock in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 23 reducing their positions, and 8 closing their positions.
4% less funds holding
Funds holding: 46 → 44 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
57% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 23
66% less capital invested
Capital invested by funds: $70.2M → $23.6M (-$46.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Greenlight Capital
New York
|
+$1.54M |
| 2 |
PCM
Prelude Capital Management
New York
|
+$157K |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$145K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$49.6K |
| 5 |
Renaissance Technologies
New York
|
+$38.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.72M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$260K |
| 3 |
JP Morgan Chase
New York
|
-$258K |
| 4 |
PP
PDT Partners
New York
|
-$140K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$139K |
TLIS Hedge Fund Activity: Q1 2022 in Review
44 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q1 2022, worth a combined $23.6M — down 66% from $70.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TLIS and 6 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 10 added.
The largest buyer was Greenlight Capital, adding an estimated $1.54M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $2.72M.
- 44 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q1 2022, down from 46 in Q4 2021.
- Funds reported $23.6M of Talis Biomedical Corporation Common Stock stock for Q1 2022, down 66% quarter-over-quarter.
- 6 funds opened new Talis Biomedical Corporation Common Stock positions in Q1 2022 and 8 closed out, a net change of -2 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q1 2022 was Greenlight Capital, an estimated $1.54M added.
- The largest Talis Biomedical Corporation Common Stock seller in Q1 2022 was ArrowMark Colorado Holdings, an estimated $2.72M sold.
Based on aggregated 13F filings for Q1 2022.